Company intelligence / Profile preview

Sequana Medical

Zug, Zug ZG, Switzerlandprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

NovaShunt developed the ALFA Pump System, a subcutaneously implanted battery-powered pump designed to remove excess abdominal fluid (ascites) in patients with advanced liver disease and other conditions. The device aimed to improve patient quality of life by automating ascites management. The company was rebranded as Sequana Medical in 2011, which continued development and commercialization of the technology.

Therapeutic areas: Gastroenterology
Modalities: Device (implantable fluid management system)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

ALFApump System

Commercial

Indications: Ascites, Liver cirrhosis, Cancer, Congestive heart failure

Beyond the preview

Go deeper on Sequana Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequana Medical.

Explore the full profile